Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

SEATTLE, April 4, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that the April 2011 edition of the peer reviewed journal, Leukemia & Lymphoma (April 2011; 52(4): 620–628) published results of a phase I/II clinical trial evaluating the effect of cyclophosphamide, pixantrone, vincristine, and prednisone ("CPOP") in treating patients with aggressive non-Hodgkin's lymphoma ("NHL") who relapsed following initial therapy with cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone ("CHOP").  In the CPOP regimen, pixantrone substitutes for doxorubicin (H) in the CHOP regimen.  Peter Borchmann, M.D., of the University Hospital of Cologne, led the study.  CPOP produced high rates of complete remissions ("CR") and overall response rate ("ORR").  In some patients, these remissions were highly durable despite patients having relapsed after receiving CHOP and other multi-agent therapies.  

The study enrolled 35 patients in the phase I portion of the trial and 30 patients in the phase II portion of the trial. A major tumor response was reported for 80% and 73% of patients in phase I and II respectively, with 57% and 47% of the patients achieving a complete or unconfirmed CR. Median overall survival in the phase II portion of the trial was 17.9 months with four patients achieving notable long-term disease-free survival ranging from 55 to 77 months, despite in some cases having failed multiple prior regimens including stem cell transplantation. High response rates were also observed in the 43% of patients who had received prior rituximab as part of their front-line regimen (CHOP-R), with an ORR rate of 77% and CR rate of 54%. Myelosuppression was the most common toxicity. Side effects (grade 3/4) in phase I of the trial included febrile neutropenia (11%), grade 3/4 infections (3%), and cardiac failure (6%). In phase II of the trial, side effects (grade 3/4) included febril
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
(Date:12/22/2014)... 22, 2014  Pfenex Inc. (NYSE MKT: PFNX) today ... has been filed and is now open and that ... Department of Health and Human Services (HHS), through the ... "We are extremely pleased to have the IND now ... a significant milestone in our company,s partnership with BARDA ...
(Date:12/22/2014)... Dec. 22, 2014 TWi Biotechnology, Inc., ... Allowance for AC-201, TWi Biotechnology,s lead drug candidate, ... China for patent application numbered ... acceptable salts, active metabolite for treatment of type ... of treatment using AC-201 for type II diabetes, ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
... 7 Aerovance Inc. today reported,pharmacokinetic (PK) and ... its Aerovant,inhalation powder that demonstrate good tolerability with ... of a single 10 mg,dose., This 10 ... doses investigated in,Aerovance,s Phase IIb dose-ranging study, which ...
... Menu Expanded to Eight On-Demand Tests for Use on the GeneXpert(R) ... ... 7 Cepheid (Nasdaq:,CPHD) today announced the release of Xpert(TM) vanA/vanB as ... Diagnostic,Medical Devices. The test delivers rapid detection of vanA and/or vanB,genes, the ...
Cached Medicine Technology:Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 3Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 4
(Date:12/22/2014)... Explorys, the leader in big data-driven healthcare ... Greg Yarrington as Vice President of Operations, Adam Wallace ... Vice President of Solutions. These new leaders are part ... 2015 to support client demand for the company’s big ... growth of its partner network. , Since the ...
(Date:12/22/2014)... The MedTech industry is gearing up for new growth ... PartnerTech AB of Sweden, is prepared to facilitate the manufacturing ... , All signs point to growth in the MedTech industry ... repeal of the excise tax originally levied to fund the ... growth of 9.3% and PartnerTech Inc. is prepared to answer ...
(Date:12/22/2014)... Branch, TX (PRWEB) December 22, 2014 ... revolutionary work glove with many useful features. Customers of ... and can have the new gloves delivered to their ... work gear and hand tools that incorporate heavy duty ... Utility Magnetic Glove allows workers to store metal parts ...
(Date:12/22/2014)... December 22, 2014 NAPW ... Professional Woman of the Year. She is recognized with ... largest, most recognized networking organization of professional women in ... National Association of Professional Women is a vibrant networking ... Chapters. , Ms. Kreider is passionate and committed to ...
(Date:12/22/2014)... Parker & Sons, Inc. a reliable and dependable ... services reports a record number of favorable reviews and ... As a company that has served the greater Phoenix ... is a business that is focused on excellent credibility ... top quality companies in Arizona that are focused on ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3
... fruitful, lead in ongoing investigation into salmonella outbreak , , ... U.S. government investigation into salmonella-tainted tomatoes has not yet ... said Monday they are now focusing their trace-back efforts ... , "The cluster is linked to the same ...
... PITTSBURGH, June 16 Mylan Inc. (NYSE: ... Inc., has,received tentative approval from the U.S. Food ... Application (ANDA) for Irbesartan and,Hydrochlorothiazide Tablets, 150 mg/12.5 ... Hydrochlorothiazide Tablets, indicated for the treatment,of hypertension, are ...
... have found a new family of therapeutic agents that ... growth of breast cancer cells. The results of the ... The Endocrine Society,s 90th Annual Meeting in San Francisco. ... therapeutic called TPBM and related compounds are likely to ...
... of agents that inhibit the growth of estrogen-dependent breast ... of the Endocrine Society, has opened an avenue of ... , "This cell-based study is exciting because it suggests ... that remain dependent on estrogen for growth but are ...
... could be the next generation of treatments, researchers say ... identified a new group of compounds that might one ... to fight estrogen-fueled breast cancer. , "This is a ... Dr. Len Lichtenfeld, deputy chief medical officer of the ...
... June 16 The National Center for Healthcare,Leadership ... Gabow, MD, chief,executive officer of Denver Health, as ... for her significant and lasting contributions,to healthcare. Under ... healthcare system that achieves organizational,excellence while treating at-risk ...
Cached Medicine News:Health News:FDA Narrowing Tainted Tomato Probe to One Cluster 2Health News:FDA Narrowing Tainted Tomato Probe to One Cluster 3Health News:Future hope for patients with breast cancers resistant to tamoxifen 2Health News:Team discovers new inhibitors of estrogen-dependent breast cancer cells 2Health News:New Molecule Discovery Shows Promise Against Tamoxifen-Resistant Breast Cancers 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 3Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: